About
ExeVir Bio develops modular antibody therapies based on camelid single domain antibody fragments (VHH) to prevent and treat infectious diseases, focusing initially on COVID-19 and dengue.
Explore ExeVir Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.